AG
DSGN icon

Algert Global’s Design Therapeutics DSGN Stock Holding History

Algert Global’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.18M Buy
204,739
+16,970
+9% +$172K 0.03% 696
2025
Q4 		$1.76M Buy
+187,769
New +$1.47M 0.03% 736
2025
Q1 		– Sell
-16,238
Closed -$100K – 1213
2024
Q4 		$100K Buy
16,238
+1,860
+13% +$10.8K ﹤0.01% 1120
2024
Q3 		$77K Buy
14,378
+1,962
+16% +$9.23K ﹤0.01% 1131
2024
Q2 		$42K Buy
12,416
+1,336
+12% +$5.21K ﹤0.01% 1450
2024
Q1 		$45K Sell
11,080
-24,540
-69% -$65.5K ﹤0.01% 1037
2023
Q4 		$94K Hold
35,620
– – ﹤0.01% 1081
2023
Q3 		$84K Buy
35,620
+16,190
+83% +$75.5K ﹤0.01% 1042
2023
Q2 		$122K Buy
+19,430
New +$119K 0.01% 1028

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Algert Global's DSGN Position: Q1 2026 in Review

Algert Global increased its Design Therapeutics (DSGN) stake by 9% in Q1 2026, buying an estimated $172K and bringing the position to 204,739 shares worth $2.18M. The position accounts for 0.03% of the portfolio, ranked #696.

Algert Global first reported a position in DSGN in Q2 2023 and has held it in 9 quarters since. 125 funds tracked by Wall St. Rank hold DSGN as of Q1 2026.

  • Algert Global held 204,739 shares of Design Therapeutics worth $2.18M as of Q1 2026.
  • Algert Global bought 16,970 Design Therapeutics shares in Q1 2026, an estimated $172K.
  • Design Therapeutics made up 0.03% of Algert Global's portfolio in Q1 2026, its #696 holding.
  • Algert Global first reported a position in Design Therapeutics in Q2 2023 and has held it in 9 quarters since.
  • 125 funds tracked by Wall St. Rank held Design Therapeutics as of Q1 2026.

Based on Algert Global's 13F filing for Q1 2026, filed 14 May 2026.